Published On : September 2026
A buyer assuming procurement structure alone predicts which commercialisation model a vendor uses is overlooking the variable that actually shapes vendor access in this market.
Within the implantable neurostimulator for epilepsy market, physician influence is the variable that most shapes the commercialisation model a vendor can use, since a neurosurgeon's or epileptologist's technology preference often determines which vendor a hospital procurement team even considers evaluating.
This page describes six end user categories and four business and commercialisation model categories strictly as market segments.
It provides no procurement negotiation guidance, and makes no claim about seizure control effectiveness or clinical efficacy for any vendor or technology.
A neurosurgeon's established technology preference generally narrows a hospital procurement team's shortlist before a formal evaluation process even begins, independent of the procurement structure that team otherwise follows.
That physician-led pattern is why manufacturers experienced in this market invest heavily in clinical relationships alongside, and often ahead of, formal procurement engagement.
Four commercialisation model categories complete the picture once end user influence is established, spanning direct sales, hospital partnership, distributor-led international expansion and reimbursement-driven market access.
Direct sales and hospital partnership models are generally paired with the most physician-influenced purchasing environments, reflecting established manufacturer relationships in North America and Western Europe.
Distributor-led international expansion and reimbursement-driven market access are generally paired with newer or less established markets, where local reimbursement structure shapes adoption pace as much as physician preference.
For buyers, understanding which end users hold the most influence over a specific evaluation is a more reliable starting point than procurement structure alone.
For manufacturers, end user and commercialisation model breadth across all categories widens the addressable share of any health system's purchasing pathway.
This physician-led pattern holds across every end user category this report tracks, since even a well-structured procurement process generally defers to an established clinical preference already in place.
For a manufacturer entering a new health system, this means the earliest and most consequential relationship to build is usually clinical rather than commercial, regardless of how that system's formal procurement process is structured.
Neurosurgeons, epileptologists and neurologists form the three most clinically influential end user categories tracked in this report.
All three are named here as market categories, and this page states nothing about how any clinician evaluates or treats a patient.
Neurosurgeons and epileptologists together represent the largest end user category by clinical involvement identified in this report.
Neurologists are generally engaged earlier in a patient's referral pathway, distinct from the surgical and specialist evaluation role typical of neurosurgeons and epileptologists.
Clinical involvement across these three end user categories tracks closely with the epilepsy indications these clinicians evaluate, since referral pathway and indication complexity shape which clinician type leads a given case.
This grouping as a whole holds the most direct influence over technology preference of any end user category tracked in this report.
For manufacturers, this grouping remains the most commercially important given its outsized influence over hospital procurement team shortlisting.
Both epileptologists and neurosurgeons are typically engaged well before a formal procurement evaluation, reflecting the clinical-evidence-led nature of technology selection in this market.
For buyers, confirming which of these three clinician types holds primary technology influence at a given centre is a reasonable qualification step before engaging a new vendor relationship.
Commercially, this end user grouping generally anchors the deepest and longest-standing manufacturer relationships of the six categories tracked in this report, given its outsized role in shaping technology preference.
For manufacturers, sustained clinical engagement across this grouping continues to shape which vendors even reach a formal hospital procurement or integrated delivery network review.
Hospital procurement teams and integrated delivery networks (IDNs) form a further end user grouping tracked in this report.
Both are named here as market categories, and this page states nothing about how either entity evaluates or negotiates a purchase.
Hospital procurement teams generally formalise a technology decision already shaped by clinical preference, rather than independently selecting a vendor.
Integrated delivery networks generally evaluate technology decisions across multiple affiliated centres, distinct from the single-centre scope typical of an individual hospital procurement team.
Commercially, this grouping requires manufacturers with established capital equipment budgeting and reimbursement documentation, narrowing the field of qualified vendors relative to physician-only engagement.
For manufacturers, integrated delivery network relationships are a meaningful differentiator given the multi-centre reach a single successful evaluation can unlock.
Buyers within this grouping generally place a higher premium on capital equipment budgeting fit and reimbursement documentation than on clinical preference alone.
Hospital procurement teams, by contrast, are more frequently engaged for single-centre evaluations with a narrower scope than a full integrated delivery network review.
For buyers, engaging both the relevant clinical champion and the procurement or integrated delivery network team early generally reduces both clinical and commercial risk on a new technology programme.
Commercially, this end user grouping continues to grow in influence as more comprehensive epilepsy centres consolidate under larger integrated delivery network structures across the regions this report tracks.
For manufacturers, building a dedicated integrated delivery network engagement function is a meaningful differentiator relative to vendors organised solely around single-centre relationships.
|
PROCUREMENT INSIGHT Integrated delivery networks increasingly formalise a technology preference that individual clinicians established well before a multi-centre procurement review begins, meaning physician relationships function as the genuine gate to a broader IDN opportunity rather than the procurement process itself. |
Academic research institutions complete the end user dimension tracked in this report.
This category is named here as a market category, and this page states nothing about how any institution conducts research or evaluates a device.
Academic research institutions are generally engaged through clinical trial collaborations and academic institution partnerships identified among this market's strategic developments.
This end user category generally requires the most extensive evidence-generation engagement of the categories tracked in this report, reflecting its research-led rather than purely clinical-care role.
Commercially, academic research institution relationships are closely tied to the clinical evidence depth and publication benchmarking metrics tracked elsewhere in this report.
For manufacturers, academic research institution capability is a differentiator for vendors building a longer-term evidence base ahead of indication expansion.
Buyers in this category are generally engaging technology at an earlier evaluation stage than a comprehensive epilepsy centre's standard clinical adoption pathway.
For manufacturers, sustained academic research institution engagement generally supports the clinical trial collaborations that in turn shape indication expansion pace across the wider market.
Commercially, this end user category generally involves a longer engagement horizon than a standard clinical evaluation, given the research and publication timelines academic settings typically operate on.
For buyers, an academic research institution's existing clinical trial collaboration portfolio is a reasonable indicator of which technology categories it is best positioned to evaluate next.
Direct sales and hospital partnership models are the two most established commercialisation model categories tracked in this report.
Both are named here as market categories, and this page states nothing about how either model is structured commercially.
The direct sales model accounts for the largest business and commercialisation model category among established manufacturers identified in this report.
Hospital partnership models generally involve a deeper, longer-term relationship structure than a standard direct sales engagement, reflecting shared investment in clinical evidence generation or programme development.
This grouping as a whole is most concentrated in North America and Western Europe, where established manufacturer relationships and reimbursement pathways are most mature.
For manufacturers, this grouping remains the most established and continues to anchor the largest share of overall commercial activity.
Both models generally require sustained clinical relationship investment, distinct from the more distributor-dependent approach typical of newer or less established markets.
Hospital partnership models, by contrast, are more frequently used where a manufacturer and centre jointly invest in programme development or evidence generation.
For buyers, understanding whether a vendor relationship is structured as direct sales or a deeper hospital partnership generally clarifies the level of joint investment a centre should expect.
Commercially, this grouping continues to anchor the majority of overall revenue for established manufacturers, even as distributor-led and reimbursement-driven models grow at a faster relative pace.
For manufacturers, sustaining direct sales and hospital partnership relationships in established markets generally funds the international commercialisation expansion pursued elsewhere in the business.
Distributor-led international expansion and reimbursement-driven market access complete the commercialisation model dimension tracked in this report.
Both are named here as market categories, and this page states nothing about how either model is structured commercially.
Distributor-led international expansion forms a fast-growing commercialisation category identified in this report, tied to manufacturers extending access beyond established North American and Western European markets.
Reimbursement-driven market access is generally the determining factor for adoption pace in newer markets, independent of clinical preference or distributor relationship strength.
Commercialisation model choice connects closely to the manufacturers each model favours, since established manufacturers and emerging or regional developers generally rely on different combinations of these four models.
Commercially, this grouping requires manufacturers with established international regulatory and reimbursement documentation, narrowing the field of vendors positioned to compete outside established markets.
For manufacturers, distributor-led international expansion capability is a meaningful differentiator given the considerable untapped opportunity identified in Asia-Pacific adoption.
Buyers in newer markets generally place a higher premium on a vendor's local reimbursement pathway documentation than on brand recognition alone.
For buyers, confirming a vendor's distributor and reimbursement pathway strength in a specific market early generally avoids mismatched market-access assumptions later in the evaluation process.
Commercially, this grouping generally requires the longest market-entry timeline of the four commercialisation categories tracked in this report, given the local regulatory and reimbursement groundwork it depends on.
For manufacturers, sequencing distributor-led entry ahead of a deeper hospital partnership approach is a common pattern once a market's reimbursement pathway becomes more established.
Six end user categories are tracked in this report: neurosurgeons, epileptologists, neurologists, hospital procurement teams, integrated delivery networks (IDNs) and academic research institutions.
A network of affiliated centres that evaluates technology decisions across multiple sites at once, distinct from the single-centre scope of an individual hospital procurement team.
Four commercialisation model categories are tracked: direct sales, hospital partnership, distributor-led international expansion and reimbursement-driven market access.
Because a neurosurgeon's or epileptologist's technology preference often determines which vendor a hospital procurement team even considers, before a formal evaluation process begins.
The direct sales model accounts for the largest business and commercialisation model category among established manufacturers, concentrated most heavily in North America and Western Europe.
Academic research institutions are generally engaged through clinical trial collaborations and academic institution partnerships, supporting the evidence base that shapes indication expansion across the wider market.